The Marked Chart Wire · Health
Obesity Drugs
Lilly reports eloralintide phase 2 results at ObesityWeek
Eli Lilly presented phase 2 data for eloralintide, showing 74% of participants reported fewer cravings and 52% less food noise. The company also shared updates on eloraTZP, retatrutide, Zepbound, and Foundayo.
Part of a series: Obesity drug pipeline and access updates
